Mitoxantrone-Melphalan Conditioning Regimen For Autologous Stem Cell Transplantation In Relapsed/Refractory Lymphoma
![](/themes/Mirage2//images/mime2.png)
View/ Open
Date
2019Author
OKAY, Müfide
BÜYÜKAŞIK, Yahya
DEMİROĞLU, Haluk
MALKAN, Ümit Yavuz
ÇİFTÇİLER, Rafiye
ALADAĞ, Elifcan
AKSU, Salih
HAZNEDAROĞLU, İbrahim Celalettin
SAYINALP, Nilgün
ÖZCEBE, Osman İlhami
GÖKER, Hakan
xmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Background/aim High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL). In this study, we report the outcome of the mitoxantrone-melphalan conditioning regimen for lymphoma. Materials and methods The study group included 53 patients who were relapsed/refractory HL (n = 14) and NHL (n = 39) and received mitoxantrone and melphalan followed by ASCT. The transplant regimen consisted of mitoxantrone (60 mg/m2) and melphalan (180 mg/m2) followed by peripheral blood stem cell infusion (PBSC). Results Prior to high-dose chemotherapy, 37.7% of the patients were in complete remission (CR) and 45.3% were in partial remission (PR), and 17% had stable or progressive disease. After high-dose chemotherapy and PBSC, 44 out of 51 patients achieved CR (86.2%). CR was achieved in 24 out of 33 patients (72.7%) who were transplanted in a marginally active phase of the disease. At a median followup of 25.4 months (1.8–131.3 months) after ASCT, 13 patients relapsed/progressed and 8 patients died. The estimated 2-year overall survival (OS) was 81.9%, and event-free survival (EFS) was 59.3%. Conclusion High-dose chemotherapy followed by ASCT is an effective conditioning regimen in relapsed/refractory lymphoma patients who are undergoing ASCT.
URI
http://dx.doi.org/10.3906/sag-1809-36https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018231/
http://hdl.handle.net/11655/23929